The Effect of PD-1 Inhibitor Combined with Irradiation on HMGB1-Associated Inflammatory Cytokines and Myocardial Injury

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Maier B, Leader AM, Chen ST, et al. Author Correction: a conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;582(7813):E17. doi:10.1038/s41586-020-2326-5
   PubMed Web of Science ®Google Scholar
• Efstathiou JA, Heunis M, Karumekayi T, et al. Establishing and delivering quality radiation therapy in resource-constrained settings: the story of botswana. J Clin Oncol. 2016;34(1):27–35. doi:10.1200/JCO.2015.62.8412
   PubMed Web of Science ®Google Scholar
• Zanoni M, Cortesi M, Zamagni A, et al. The role of mesenchymal stem cells in radiation-induced lung fibrosis. Int J Mol Sci. 2019;20(16):3876. doi:10.3390/ijms20163876
   PubMed Web of Science ®Google Scholar
• Kim SH, Cho E, Kim YI, et al. Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells. Nat Commun. 2021;12(1):5314. doi:10.1038/s41467-021-25559-7
   PubMed Web of Science ®Google Scholar
• Chauhan P, Lokensgard JR. Glial cell expression of PD-L1. Int J Mol Sci. 2019;20(7):1677. doi:10.3390/ijms20071677
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Choi J, Mani N, et al. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun. 2018;9(1):3196. doi:10.1038/s41467-018-05032-8
   PubMed Web of Science ®Google Scholar
• Ngwa W, Irabor OC, Schoenfeld JD, et al. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18(5):313–322. doi:10.1038/nrc.2018.6
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR, Liang H, Deng L, et al. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365–379. doi:10.1038/nrclinonc.2016.211
   PubMed Web of Science ®Google Scholar
• Díaz-Gavela AA, Figuaeiras-Graillet L, Luis ÁM, et al. Breast radiotherapy-related cardiotoxicity. when, how, why. risk prevention and control strategies. Cancers. 2021;13(7):1712. doi:10.3390/cancers13071712
   PubMed Web of Science ®Google Scholar
• Weigel C, Schmezer P, Plass C, et al. Epigenetics in radiation-induced fibrosis. Oncogene. 2015;34(17):2145–2155. doi:10.1038/onc.2014.145
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. doi:10.1016/S0140-6736(18)30533-6
   PubMed Web of Science ®Google Scholar
• Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–1589. doi:10.1016/S1470-2045(18)30608-9
   PubMed Web of Science ®Google Scholar
• Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9(12):1477–1483. doi:10.1038/nm955
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755. doi:10.1056/NEJMoa1609214
   PubMed Web of Science ®Google Scholar
• Du S, Zhou L, Alexander GS, et al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol. 2018;13(4):510–520. doi:10.1016/j.jtho.2017.12.002
   PubMed Web of Science ®Google Scholar
• Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4):331–342. doi:10.1038/nri1594
   PubMed Web of Science ®Google Scholar
• Li R, Zou X, Huang H, et al. HMGB1/PI3K/Akt/mTOR signaling participates in the pathological process of acute lung injury by regulating the maturation and function of dendritic cells. Front Immunol. 2020;11:1104. doi:10.3389/fimmu.2020.01104
   PubMed Web of Science ®Google Scholar
• Mori DN, Kreisel D, Fullerton JN, et al. Inflammatory triggers of acute rejection of organ allografts. Immunol Rev. 2014;258(1):132–144. doi:10.1111/imr.12146
   PubMed Web of Science ®Google Scholar
• Lu H, Zhang Z, Barnie PA, et al. Dual faced HMGB1 plays multiple roles in cardiomyocyte senescence and cardiac inflammatory injury. Cytokine Growth Factor Rev. 2019;47:74–82. doi:10.1016/j.cytogfr.2019.05.009
   PubMed Web of Science ®Google Scholar
• Mole DJ, Webster SP, Uings I, et al. Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis. Nat Med. 2016;22(2):202–209. doi:10.1038/nm.4020
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi:10.1056/NEJMoa1809697
   PubMed Web of Science ®Google Scholar
• Durm G, Althouse S, Sadiq A, et al. OA01.07 updated results of a Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III NSCLC. J Thorac Oncol. 2018;13:S321. doi:10.1016/j.jtho.2018.08.238
   Web of Science ®Google Scholar
• Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276–1282. doi:10.1001/jamaoncol.2019.1478
   PubMed Web of Science ®Google Scholar
• Lin S, Lin X, Clay D, et al. OA01.06 DETERRED: Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(10):S320–S321. doi:10.1016/j.jtho.2018.08.237
   Web of Science ®Google Scholar
• Peters S, Ruysscher D, Dafni U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: the ETOP NICOLAS phase II trial. J Clin Oncol. 2018;36:8510. doi:10.1200/JCO.2018.36.15_suppl.8510
   Web of Science ®Google Scholar
• Pellegrini L, Foglio E, Pontemezzo E, et al. HMGB1 and repair: focus on the heart. Pharmacol Ther. 2019;196:160–182. doi:10.1016/j.pharmthera.2018.12.005
   PubMed Web of Science ®Google Scholar
• Zhu M, Yang M, Zhang J, et al. Immunogenic cell death induction by ionizing radiation. Front Immunol. 2021;12:705361. doi:10.3389/fimmu.2021.705361
   PubMed Web of Science ®Google Scholar
• Sato H, Okonogi N, Nakano T. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol. 2020;25(5):801–809. doi:10.1007/s10147-020-01666-1
   PubMed Web of Science ®Google Scholar
• Xu H, Su Z, Wu J, et al. The alarmin cytokine, high mobility group box 1, is produced by viable cardiomyocytes and mediates the lipopolysaccharide-induced myocardial dysfunction via a TLR4/phosphatidylinositol 3-kinase gamma pathway. J Immunol. 2010;184(3):1492–1498. doi:10.4049/jimmunol.0902660
   PubMed Web of Science ®Google Scholar
• Yao Y, Xu X, Zhang G, et al. Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway. Basic Res Cardiol. 2012;107(3):267. doi:10.1007/s00395-012-0267-3
   PubMed Web of Science ®Google Scholar
• Caushi JX, Zhang J, Ji Z, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers [published correction appears in Nature. 2021 Oct;598(7881):E1]. Nature. 2021;596(7870):126–132. doi:10.1038/s41586-021-03752-4
   PubMed Web of Science ®Google Scholar
• Oladiran O, Shi XQ, Yang M, et al. Inhibition of TLR4 signaling protects mice from sensory and motor dysfunction in an animal model of autoimmune peripheral neuropathy. J Neuroinflammation. 2021;18(1):77. doi:10.1186/s12974-021-02126-x
   PubMed Web of Science ®Google Scholar
• Xiong X, Gu L, Wang Y, et al. Glycyrrhizin protects against focal cerebral ischemia via inhibition of T cell activity and HMGB1-mediated mechanisms. J Neuroinflammation. 2016;13(1):241. doi:10.1186/s12974-016-0705-5
   PubMed Web of Science ®Google Scholar
• Zhang T, Guan XW, Gribben JG, et al. Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma. Cell Death Dis. 2019;10(5):330. doi:10.1038/s41419-019-1563-8
   PubMed Web of Science ®Google Scholar
• Huang J, Liu K, Yu Y, et al. Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy. 2012;8(2):275–277. doi:10.4161/auto.8.2.18940
   PubMed Web of Science ®Google Scholar
• Hubert P, Roncarati P, Demoulin S, et al. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. J Immunother Cancer. 2021;9(3):e001966. doi:10.1136/jitc-2020-001966
   PubMed Web of Science ®Google Scholar
• Anurupa D, Shankar I, Bahram R, et al. NF-κB and innate immunity. Curr Top Microbiol Immunol. 2011;349:115–143. doi:10.1007/82_2010_102
   PubMed Web of Science ®Google Scholar
• Liu S, Chen ZJ. Expanding role of ubiquitination in NF-κB signaling. Cell Res. 2011;21(1):6–21. doi:10.1038/cr.2010.170
   PubMed Web of Science ®Google Scholar
• Zheng L, Zhu Q, Xu C, et al. Glycyrrhizin mitigates radiation-induced acute lung injury by inhibiting the HMGB1/TLR4 signalling pathway. J Cell Mol Med. 2020;24(1):214–226. doi:10.1111/jcmm.14703
   PubMed Web of Science ®Google Scholar
• Sandanger Ø, Ranheim T, Vinge LE, et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2013;99(1):164–174. doi:10.1093/cvr/cvt091
   PubMed Web of Science ®Google Scholar
• Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3(105):cm1. doi:10.1126/scisignal.3105cm1
   PubMed Web of Science ®Google Scholar
• Dusser P, Koné-Paut I. IL-1 inhibition may have an important role in treating refractory Kawasaki disease. Front Pharmacol. 2017;8:163. doi:10.3389/fphar.2017.00163
   PubMed Web of Science ®Google Scholar
• Yahyapour R, Amini P, Rezapour S, et al. Radiation-induced inflammation and autoimmune diseases. Mil Med Res. 2018;5(1):9. doi:10.1186/s40779-018-0156-7
   PubMed Web of Science ®Google Scholar
• Mezzaroma E, Mikkelsen RB, Toldo S, et al. Role of interleukin-1 in radiation-induced cardiomyopathy. Mol Med. 2015;21(1):210–218. doi:10.2119/molmed.2014.00243
   PubMed Web of Science ®Google Scholar
• Christersdottir T, Pirault J, Gisterå A, et al. Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade. Eur Heart J. 2019;40(30):2495–2503. doi:10.1093/eurheartj/ehz206
   PubMed Web of Science ®Google Scholar
• Saibil SD, Bonilla L, Majeed H, et al. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab. Curr Oncol. 2019;26(3):e418–e421. doi:10.3747/co.26.4381
   PubMed Web of Science ®Google Scholar
• Lyman M, Lieuw V, Richardson R, et al. A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases. J Biol Chem. 2018;293(24):9326–9334. doi:10.1074/jbc.M117.818559
   PubMed Web of Science ®Google Scholar
• Mantovani A, Barajon I, Garlanda C. IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev. 2018;281(1):57–61. doi:10.1111/imr.12614
   PubMed Web of Science ®Google Scholar
• Kampan NC, Xiang SD, McNally OM, et al. Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: challenges and oppidufanyiortunities. Curr Med Chem. 2018;25(36):4785–4806. doi:10.2174/0929867324666170712160621
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao J, Lau WB, et al. Tumor necrosis factor-α and lymphotoxin-α mediate myocardial ischemic injury via TNF receptor 1, but are cardioprotective when activating TNF receptor 2. PLoS One. 2013;8(5):e60227. doi:10.1371/journal.pone.0060227
   PubMed Web of Science ®Google Scholar
• Cherng SH, Huang CY, Kuo WW, et al. GABA tea prevents cardiac fibrosis by attenuating TNF-alpha and Fas/FasL-mediated apoptosis in streptozotocin-induced diabetic rats. Food Chem Toxicol. 2014;65:90–96. doi:10.1016/j.fct.2013.12.022
   PubMed Web of Science ®Google Scholar
• Liao W, Rao Z, Wu L, et al. Cariporide attenuates doxorubicin-induced cardiotoxicity in rats by inhibiting oxidative stress, inflammation and apoptosis partly through regulation of Akt/GSK-3β and Sirt1 signaling pathway. Front Pharmacol. 2022;13:850053. doi:10.3389/fphar.2022.850053
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Kearney CJ, Silke J, et al. Unleashing TNF cytotoxicity to enhance cancer immunotherapy. Trends Immunol. 2021;42(12):1128–1142. doi:10.1016/j.it.2021.10.003
   PubMed Web of Science ®Google Scholar